Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

BACKGROUND: The lack of adequate randomized clinical trials (RCT) has hindered identification of new therapies that are safe and effective for patients with primary focal segmental glomerulosclerosis (FSGS), especially in patients who fail to respond to corticosteroids and immunosuppressive therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Trachtman, Howard, Vento, Suzanne, Gipson, Debbie, Wickman, Larysa, Gassman, Jennifer, Joy, Melanie, Savin, Virginia, Somers, Michael, Pinsk, Maury, Greene, Tom
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045306/
https://www.ncbi.nlm.nih.gov/pubmed/21310077
http://dx.doi.org/10.1186/1471-2369-12-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045306/
https://www.ncbi.nlm.nih.gov/pubmed/21310077
http://dx.doi.org/10.1186/1471-2369-12-8

Ejemplares similares